Skip to main content

Advertisement

SpringerLink
Log in

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The clinical activity of combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer was evaluated retrospectively.

Methods

Intravenous CPT-11 was given at 60 mg/m2 (days 1, 8, 15), followed by NDP 80 mg/m2 (day 1), every 4 weeks.

Results

According to the medical records, 29 cases have received this regimen since 2000. Median age was 57 years (range, 29–80), and performance status (PS) of the patients was 18 cases with PS 0, 10 cases with PS 1, and 1 case with PS 2, respectively. Clinical stage was as follows: 3 cases of stage Ib1, 2 cases of Ib2, 2 cases of IIa, 10 cases of IIb, 8 cases of IIIb, and 4 cases of IVb. There were 27 cases of squamous cell carcinoma and 2 cases of adenocarcinoma. Concerning hematological toxicity of grade 3 or more, neutropenia, leukopenia, and febrile neutropenia were observed in 79.3 %, 96.6 %, and 13.8 % of cases, respectively. For nonhematological toxicity, nausea, anorexia, joint pain, and confusion were observed in only 1 case, respectively, and as a result, in 7 cases chemotherapy was not completed. Among 26 cases with clinically evaluable lesions, there were 7 complete responses, 3 partial responses, 7 stable disease, and 9 progressive disease; the clinical response rate was 38.5 %. Median progression-free survival was 7 months (range, 0–38 months).

Conclusion

The combination of CPT-11 and NDP seems to be active for patients with recurrent uterine cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Treatment Guidelines for Cervical Cancer (2011) (in Japanese). Kanehara, Tokyo, pp 147–153

  2. Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Sugiyama T, Yakushiji M, Noda K et al (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced and recurrent cervical cancer. Oncology 58:31–37

    Article  CAS  PubMed  Google Scholar 

  4. Noda K, Ikeda M, Yakushiji M et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus (in Japanese). Gan To Kagaku Ryoho 19:885–892

    CAS  PubMed  Google Scholar 

  5. Tsuda H, Hashiguchi Y, Nishimura S et al (2004) Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032–1037

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Bonomi P, Blessing JA, Stehman FB et al (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079–1085

    CAS  PubMed  Google Scholar 

  7. Omura GA, Blessing JA, Vaccarello L et al (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15:165–171

    CAS  PubMed  Google Scholar 

  8. Bloss JD, Blessing JA, Behrens BC et al (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 20:1832–1837

    Article  CAS  PubMed  Google Scholar 

  9. Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVb, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22:3113–3119

    Article  CAS  PubMed  Google Scholar 

  10. Long HJ III, Bundy BN, Grendys EC Jr et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23:4626–4633

    Article  CAS  PubMed  Google Scholar 

  11. Thigpen JT (2003) The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 9:425–432

    Article  CAS  PubMed  Google Scholar 

  12. Rose PG, Blessing JA, Gershenson DM et al (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 17:2676–2680

    CAS  PubMed  Google Scholar 

  13. Kato T, Nishimura H, Yakushiji M et al (1992) Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer (in Japanese). Gan To Kagaku Ryoho 19:695–701

    CAS  PubMed  Google Scholar 

  14. Pectasides D, Fountzilas G, Papaxoinis E et al (2009) Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer 19:777–781

    Article  PubMed  Google Scholar 

  15. Kosmas C, Mylonakis N, Tsakonas G et al (2009) Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. Br J Cancer 101:1059–1065

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, School of Medicine, St. Marianna University, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan

    Tatsuru Ohara, Ayako Yoshida, Norihito Yoshioka, Namiko Yahagi, Haruhiro Kondo, Akiko Tozawa, Kazushige Kiguchi & Nao Suzuki

  2. Department of Obstetrics and Gynecology, School of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan

    Yoichi Kobayashi

Authors
  1. Tatsuru Ohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoichi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ayako Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norihito Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Namiko Yahagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haruhiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akiko Tozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazushige Kiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nao Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nao Suzuki.

About this article

Cite this article

Ohara, T., Kobayashi, Y., Yoshida, A. et al. Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer. Int J Clin Oncol 18, 1102–1106 (2013). https://doi.org/10.1007/s10147-012-0487-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0487-4

Keywords

Search

Navigation